The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press49510.17650/1818-8338-2022-16-2-K665REVIEWОБЗОРInterleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritisИнгибитор интерлейкина 17А секукинумаб в лечении пациентов с псориатическим артритомhttps://orcid.org/0000-0003-4669-1006ShostakN. A.ШостакН. А.
Russian Federation

1 Ostrovityanova St., Moscow 117997

117997 Москва, ул. Островитянова, 1

https://orcid.org/0000-0001-8266-6022AndriyashkinaD. Yu.АндрияшкинаД. Ю.
Russian Federation

Daria Yurievna Andriyashkina 

1 Ostrovityanova St., Moscow 117997

Дарья Юрьевна Андрияшкина 

117997 Москва, ул. Островитянова, 1

andryashkina.darya@yandex.ruhttps://orcid.org/0000-0002-0429-3117DvornikovA. S.ДворниковА. С.
Russian Federation

1 Ostrovityanova St., Moscow 117997

117997 Москва, ул. Островитянова, 1

https://orcid.org/0000-0002-0652-2884BabadaevN.  M.БабадаеваН. М.
Russian Federation

1 Ostrovityanova St., Moscow 117997

117997 Москва, ул. Островитянова, 1

https://orcid.org/0000-0002-8874-3663SomovD. V.СомовД. В.
Russian Federation

1 Ostrovityanova St., Moscow 117997

117997 Москва, ул. Островитянова, 1

Department of Faculty Therapy named after Academician A. I. Nesterov, Pirogov Russian National Research Medical University, Ministry of Health of RussiaКафедра факультетской терапии им. академика А. И. Нестерова ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава РоссииDepartment of Dermatovenerology named after Academician Yu. K. Skripkin, Pirogov Russian National Research Medical University, Ministry of Health of RussiaКафедра дерматовенерологии им. академика Ю. К. Скрипкина ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России1504202216227391010202210102022Copyright ©; 2022, Shostak N.A., Andriyashkina D.Y., Dvornikov A.S., Babadaev N.M., Somov D.V.Copyright ©; 2022, Шостак Н.А., Андрияшкина Д.Ю., Дворников А.С., Бабадаева Н.М., Сомов Д.В.2022Shostak N.A., Andriyashkina D.Y., Dvornikov A.S., Babadaev N.M., Somov D.V.Шостак Н.А., Андрияшкина Д.Ю., Дворников А.С., Бабадаева Н.М., Сомов Д.В.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/495

Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis and characterized by various presentation, course, and response to treatment. A better understanding of the pathogenesis has led to the development of targeted therapeutic agents and innovative treatment strategies for PsA. The article is dedicated to a drug targeting interleukin-17A. Secukinumab is a fully human monoclonal antibody that selectively targets interleukin (IL) 17A, a pro-inflammatory cytokine involved in the pathogenesis of PsA. Secukinumab is the first antibody against IL 17 approved in many countries for PsA treatment in adult patients. In the Phase III FUTURE trial, secukinumab 150 and 300 mg subcutaneously showed high efficacy on disease activity in patients previously treated with non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and / or tumor necrosis factor (TNF) inhibitors and maintaining the effect for a long time of treatment (more than 5 years). In addition, in studies FUTURE 1 and 5 secukinumab suppressed structural joint damage and was associated with consistently low rates of radiological progression after 1–3 years of treatment. Treatment with secukinumab improved physical function and quality of life and was generally well tolerated in both short and long term. Secukinumab is effective in all key PsA domains and therefore represents a treatment option that may be an alternative to TNF inhibitors and other DMARDs in adult patients with PsA.

Псориатический артрит – хроническое воспалительное заболевание суставов, связанное с псориазом, которое отличается разнообразием в проявлении болезни, течении и реакции на лечение. Лучшее понимание патогенеза привело к разработке целевых терапевтических агентов и инновационных стратегий лечения псориатического артрита. Статья посвящена препарату, нацеленному на путь Т-хелперов 17, в частности интерлейкину 17A. Секукинумаб – полностью человеческое моноклональное антитело, которое избирательно нацелено на интерлейкин 17А, провоспалительный цитокин, участвующий в патогенезе псориатического артрита. Секукинумаб – первый среди антител против интерлейкина 17, одобрен во многих странах мира для лечения взрослых пациентов с псориатическим артритом. В III фазе исследования FUTURE секукинумаб, вводимый подкожно в дозах 150 и 300 мг, показал высокую эффективность в отношении активности заболевания у пациентов, ранее получавших лечение нестероидными противовоспалительными препаратами, базисными противоревматическими препаратами и / или ингибиторами фактора некроза опухоли, и сохранение эффекта в течение длительного времени лечения (более 5 лет). Кроме того, в исследованиях FUTURE 1 и 5 секукинумаб подавлял структурное повреждение суставов и был связан с устойчиво низкими показателями рентгенологического прогрессирования через 1–3 года лечения. Лечение секукинумабом улучшило физическую функцию и качество жизни и в целом хорошо переносилось как в краткосрочной, так и в долгосрочной перспективе. Секукинумаб эффективен во всех ключевых доменах псориатического артрита и поэтому представляет собой вариант лечения, который может быть альтернативой ингибиторам фактора некроза опухоли и другим базисным противоревматическим препаратам у взрослых пациентов с данным заболеванием

psoriatic arthritistreatment of psoriatic arthritissecukinumabinterleukin-17 inhibitorbiological basic anti-inflammatory drugsgenetically engineered biological drugsentesitisdactylitisspondylitisinflammatory arthritisпсориатический артритлечение псориатического артритасекукинумабингибитор интерлейкина 17биологические базисные противовоспалительные препаратыгенно-инженерные биологические препаратыэнтезитдактилитспондилитвоспалительный артритHackett S., Coates L. Psoriatic arthritis: an up to date overview. Indian J Rheumatol 2020;15(1):45–51. DOI: 10.4103/0973-3698.284751Lila A.M., Nasonov E.L., Korotaeva T.V. Psoriatic arthritis: pathogenetic features and innovative therapies. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice 2018;56(6):685–91. (In Russ.) DOI: 10.14412/1995-4484-2018-685-691Лила А.М., Насонов Е.Л., Коротаева Т.В. Псориатический артрит: патогенетические особенности и инновационные методы терапии. Научно-практическая ревматология 2018;56(6):685–91. DOI: 10.14412/1995-4484-2018-685-691Ogdie A., Coates L.C., Gladman D.D. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford) 2020;59(1):37–46. DOI: 10.1093/rheumatology/kez383Korotaeva T.V., Korsakova Yu.I. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Naychno-prakticheskaya revmatologiya = Rheumatology Science and Practice 2018;56(1):60–9. (In Russ.) DOI: 10.14412/1995-4484-2018-60-69Коротаева Т.В., Корсакова Ю.Л. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология 2018;56(1):60–9. DOI: 10.14412/1995-4484-2018-60-69Mishina O.S., Dvornikov A.S., Dontsova E.V. Analysis of the incidence of psoriasis and psoriatic arthritis in the Russian Federation for 2009-2011. Doktor Ru = Dr.Ru 2013;4(82):52–5.Мишина О.С., Дворников А.С., Донцова Е.В. Анализ заболеваемости псориазом и псориатическим артритом в Российской Федерации за 2009–2011 гг. Доктор.Ру Review 2013;4(82):52–5.Toussi A., Maverakis N., Le S.T. et al. Updated therapies for the management of psoriatic arthritis. Clin Immunol 2020;220:108536. DOI: 10.1016/j.clim.2020.108536Clegg D.O., Reda D.J., Mejias E. et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39(12):2013–20. DOI: 10.1002/art.1780391210Mease P.J., Goffe B.S., Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9227):385–90. DOI: 10.1016/S0140-6736(00)02530-7Antoni C.E., Kavanaugh A., Kirkham B. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis-controlled trial (IMPACT). Arthritis Rheum 2005;52(4):1227–36. DOI: 10.1002/art.20967Mease P., Kivitz A., Burch F. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264–72. DOI: 10.1002/art.20335Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64(8):1150–57. DOI: 10.1136/ard.2004.032268Mease P., Gladman D., Ritchlin C. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of ADEPT. Arthritis Rheum 2005;52(10):3279–89. DOI: 10.1002/art.21306Kavanaugh A., Mcinnes I., Mease P. et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twentyfour-week efficacy and safety results of a randomized, placebocontrolled study. Arthritis Rheum 2009;60(4):976–86. DOI: 10.1002/art.24403Mease P.J., Fleischmann R., Deodhar A.A. et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 doubleblind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73(1):48–55. DOI: 10.1136/annrheumdis-2013-eular.2023Mease P.J. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness TherapyFatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011;63 (11):64–85. DOI: 10.1002/acr.20577Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol 2013;25(3):287–96. DOI: 10.1136/ard.2010.140582Mease P., Collier D., Karki C. et al. Persistence and predictors of biologic TNFi therapy among biologic naïve psoriatic arthritis patients in a US registry. Arthritis Rheum 2014;66(10):abs 1853. DOI: 10.21203/rs.3.rs-78064/v1Fagerli K.M., Lie E., van der Heijde D. et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73(1):132–7. DOI: 10.1136/annrheumdis-2012-202347Jorgensen T.S., Kristensen L.E., Christensen R. et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologic’s registry. Rheumatology (Oxford) 2015;54(12):2156–65. DOI: 10.1093/rheumatology/kev216Mease P.J., Gladman D.D., Keystone E.C. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebocontrolled study. Arthritis Rheum 2006;54(5):1638–45. DOI: 10.1002/art.21870Mease P.J. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011;70(1):77–84. DOI: 10.1136/ard.2010.140582Patel D.D., Lee D.M., Kolbinger F. et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72(2):116–23. DOI: 10.14412/1996-7012-2013-04Van den Berg W.B., Mclnnes I.B. Th17 cells and IL-17a – focus on immunopathogenesis and therapeutics. Semin Arthritis Rheum 2013;43(2):158–70. DOI: 10.1016/j.semarthrit.2013.04.006Frleta M., Siebert S., Mclnnes I.B. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep 2014;16(4):414. DOI: 10.1007/s11926-014-0414-yLories R.J., Mclnnes I.B. Primed for inflammation: enthesisresident T cells. Nat Med 2012;18(7):1018–9. DOI: 10.1038/nm.2854McGonagle D., Lories R.J., Tan A.L. et al. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007;56(8):2482–91. DOI: 10.1002/art.22758Mease P.J. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015;27(2):127–33. DOI: 10.1097/BOR.0000000000000147Novartis. COSENTYX® (secukinumab) injection: US prescribing information. 2020. https://dailymed.nlm.nih.gov. Accessed 18 Jan 2021.European Medicines Agency. Secukinumab (Cosentyx): EU summary of product characteristics. 2020. https://www.ema.europa.eu. Accessed 18 Jan 2021.Mease P.J., Mclnnes I.B., Kirkham B. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373(14):1329–39. DOI: 10.1056/NEJMoa1412679Mclnnes I.B., Mease P.J., Kirkham B. Secukinumab, a human antiinterleukin-17A monoclonal antibody, in patients with psoriatic Secukinumab: A Review 493 arthritis (FUTURE 2): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 2015;386(9999):1137–46. DOI: 10.1016/S0140-6736(15)61134-5Nash P., Mease P.J., McInnes I.B. et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 2018;20(1):47. DOI: 10.1186/s13075-018-1551-xKivitz A.J., Nash P., Tahir H. et al. Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol Ther 2019;6(3):393–407. DOI: 10.1007/s40744-019-0163-5Mease P., van der Heijde D., Landewe R. et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018;77(6):890–7. DOI: 10.1136/annrheumdis-2017-212687Baraliakos X., Gossec L., Pournara E. et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021;80(5):582–90. DOI: 10.1136/annrheumdis2020-218808Оstino M., Schett G., Lopez-Rdz A. et al. Secukinumab signifcantly decreased joint synovitis measured by power doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled phase III study. Br J Rheumatol 2020; 60(1):100–1. DOI: 10.1093/rheumatology/keab247.182Mclnnes I.B., Behrens F., Mease P.J. et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active controlled, phase 3b trial. Lancet 2020;395(10235):1496–5. DOI: 10.1016/S0140-6736(20)31205-8Van der Heijde D., Mease P.J., Landewe R.B.M. et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford) 2020;59(6):1325–34. DOI: 10.1093/rheumatology/kez420Mease P.J., Landewe R.B.M., Rahman P. et al. Subcutaneous secukinumab 300 mg and 150 mg provides sustained inhibition of radiographic progression in psoriatic arthritis over 2 years: results from the phase 3 FUTURE-5 trial [abstract no. LB0006]. Ann Rheum Dis 2019;78(2):262. DOI: 10.1136/annrheumdis-2019-eular.8808Mclnnes I.B., Mease P.J., Ritchlin C.T. et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2-year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford) 2017;56(11):1993–2003. DOI: 10.1093/rheumatology/kex301Kavanaugh A., Mease P.J., Reimold A.M. et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res 2017;69(3):347–55. DOI: 10.1002/acr.23111.Mease P.J., Kavanaugh A., Reimold A. et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol 2020;2(1):18–25. DOI: 10.1002/acr2.11097Mease P.J., Kavanaugh A., Reimold A. et al. Secukinumab in the treatment of psoriatic arthritis: efcacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open 2018;4(2):e000723. DOI: 10.1136/rmdopen-2018-000723Nash P., McInnes I.B., Rahman P. et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year results from the phase 3 FUTURE 2 study [abstract no. THU0322]. Ann Rheum Dis 2018;77(2):379. DOI: 10.1136/rmdopen-2018-000723.Mclnnes I.B., Mease P.J., Kivitz A.J. et al. Long-term efcacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol 2020;2(4):e227–35. DOI: 10.1016/S2665-9913(20)30036-9Van der Heijde D., Landewe R.B., Mease P.J. et al. Secukinumab provides signifcant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol 2016;68(8):1914–21. DOI: 10.1002/art.39685Strand V., Mease P., Gossec L. et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis 2017;76(1):203–7. DOI: 10.1136/annrheumdis-2015-209055Mclnnes I.B., Mease P.J., Schett G. et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res Ther 2018;20(1):113. DOI: 10.1136/annrheumdis-2015-209055Coates L.C., Mease P.J., Gossec L. et al. Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res 2018;70(10):1529–35. DOI: 10.1002/acr.23537Coates L.C., Gladman D.D., Nash P. et al. Secukinumab provides sustained PASDAS-defned remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther 2018;20(1):272. DOI: 10.1186/s13075-018-1773-yCoates L.C., Nash P., Kvien T.K. et al. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Semin Arthritis Rheum 2020;50(4):709–18. DOI: 10.1016/j.semarthrit.2020.03.015D’Agostino M., Schett G., Lopez-Rdodriguez A. et al. Secukinumab significantly decreased joint synovitis measured by power doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled phase 3 study. Rheumatology (Oxford) 2021;60(1):P187. DOI: 10.1093/rheumatology/keab247.182Chimenti M.S., Fonti G.L., Conigliaro P. et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther 2020;20(7):813–21. DOI: 10.1080/14712598.2020.1761957Conaghan P.G., Holdsworth E., Tian H. et al. Real world efectiveness of secukinumab in psoriatic arthritis: fndings from a recent cross-sectional survey of rheumatologists and patients in Europe [abstract no. AB0755]. Ann Rheum Dis 2020;79(1):1674–5. DOI: 10.1136/annrheumdis2020-eular.1374Kiltz U., Peterlik D., Winkelmann V. et al. AQUILA study in Germany – real world data on secukinumab’s efectiveness in psoriatic arthritis patients – results from an interim analysis [abstract no. FRI0405]. Ann Rheum Dis 2019;78(2):889–90. DOI: 10.1136/annrheumdis-2019-eular.436Mease P.J., Blachley T., Glynn M. et al. Secukinumab improves clinical and patient-reported outcomes at 6 months among patients with psoriatic arthritis in the US-based Corrona psoriatic arthritis/ spondyloarthritis (PsA/SpA) registry [abstract no. SAT0429]. Ann Rheum Dis 2020;79(1):1169. DOI: 10.1136/annrheumdis-2020-eular.1014Favalli E.G., Marchesoni A., Balduzzi S. et al. Effectiveness and retention rate of secukinumab for psoriatic arthritis and axial spondyloarthritis: real-life data from the Italian LORHEN registry [abstract no. FRI0273]. Ann Rheum Dis 2020;79(1):722–3. DOI: 10.1136/annrheumdis-2020-eular.3197Lorenzin M., Carletto A., Foti R. et al. Effectiveness and safety of secukinumab in naive or TNF-inhibitors failure psoriatic arthritis patients in real life: a 24-months prospective multicenter study [abstract no. FRI0284]. Ann Rheum Dis 2020;79(1):730. DOI: 10.1136/annrheumdis-2020-eular.3702Magrey M., Bozyczko M., Wolin D. et al. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving secukinumab. Clin Drug Investig 2019;39(12):1205–12. DOI: 10.1007/s40261-019-00856-8Martin L.M., Valero M., Emperiale V. et al. Real-world experience of secukinumab for psoriatic arthritis [abstract no. FRI0448]. Ann Rheum Dis. 2019;78(2):915. DOI: 10.1136/annrheumdis-2019-eular.7452Holdsworth E., Booth N., Lobosco S. et al. Real-world physician satisfaction with secukinumab in psoriatic arthritis and ankylosing spondylitis in Europe [abstract no. THU0635]. Ann Rheum Dis 2019;78(2):611–2. DOI: 10.1136/annrheumdis-2019-eular.4167Michelsen B., Georgiadis S., Giuseppe D.I. et al. Secukinumab effectiveness in 1543 patients with psoriatic arthritis treated in routine clinical practice in 13 European countries in the EuroSpA research collaboration network [abstract no. SAT0430]. Ann Rheum Dis 2020;79(1):1169–71. DOI: 10.1136/annrheumdis2020-eular.1413Kiltz U., Peterlik D., Winkelmann V. AQUILA study in Germany – real world adherence and persistence of secukinumab treatment in ankylosing spondylitis and psoriatic arthritis patients – an interim analysis [abstract no. AB0705]. Ann Rheum Dis. 2019;78(2):1814–5. DOI: 10.1136/annrheumdis-2019-eular.435Oelke K.R., Chambenoit O., Majjhoo A.Q. et al. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Ef Res 2019;8(8):607–22. DOI: 10.2217/cer-2019-002Elewski B.E., Baddley J.W., Deodhar A.A. et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol 2021;157(1):43–51. DOI: 10.1001/jamadermatol.2020.3257Deodhar A., McInnes I., Baraliakos X. et al. Secukinumab demonstrates a consistent safety profle in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analysis [abstract no. FRI0272]. Ann Rheum Dis 2020;79(1):722. DOI: 10.1093/rheumatology/kez107.073Deodhar A., Gladman D.D., Mclnnes I.B. et al. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol 2020;47(4):539–47. DOI: 10.3899/jrheum.190116Gossec L., Baraliakos X., Kerschbaumer A. et al. EULAR recommendations for the management of psoriatic rthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79(6):700–12. DOI: 10.1136/annrheumdis-2020-217159Coates L.C., Kavanaugh A., Mease P.J. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016;68(5):1060–71. DOI: 10.1002/art.39573Singh J.A., Guyatt G., Ogdie A. et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019;71(1):5–32. DOI: 10.1002/acr.23789